Your browser is no longer supported. Please, upgrade your browser.
ADPT Adaptive Biotechnologies Corporation daily Stock Chart
Adaptive Biotechnologies Corporation
Index- P/E- EPS (ttm)-0.44 Insider Own4.70% Shs Outstand128.90M Perf Week-6.49%
Market Cap5.56B Forward P/E- EPS next Y-0.80 Insider Trans- Shs Float109.52M Perf Month7.21%
Income-52.60M PEG- EPS next Q-0.16 Inst Own62.00% Short Float1.32% Perf Quarter-
Sales58.60M P/S94.83 EPS this Y-8.50% Inst Trans- Short Ratio1.51 Perf Half Y-
Book/sh-2.40 P/B- EPS next Y9.10% ROA- Target Price43.80 Perf Year-
Cash/sh3.28 P/C13.14 EPS next 5Y- ROE- 52W Range34.11 - 51.00 Perf YTD6.97%
Dividend- P/FCF- EPS past 5Y- ROI19.30% 52W High-15.47% Beta-
Dividend %- Quick Ratio5.80 Sales past 5Y- Gross Margin64.70% 52W Low26.39% ATR2.86
Employees346 Current Ratio5.90 Sales Q/Q127.80% Oper. Margin- RSI (14)- Volatility6.78% 7.18%
OptionableYes Debt/Eq- EPS Q/Q-32.20% Profit Margin- Rel Volume0.26 Prev Close45.72
ShortableYes LT Debt/Eq- EarningsAug 13 AMC Payout- Avg Volume955.79K Price43.11
Recom1.60 SMA204.27% SMA506.79% SMA2006.79% Volume248,637 Change-5.71%
Jul-23-19Initiated BTIG Research Buy $46
Jul-22-19Initiated William Blair Outperform
Jul-22-19Initiated Guggenheim Buy $47
Jul-22-19Initiated Goldman Neutral $32
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BofA/Merrill Buy $45
Aug-16-19 04:22PM  Andreas Halvorsen's Top 5 Buys of the 2nd Quarter
Aug-14-19 09:05AM  Adaptive Biotechnologies stock down 8.5% in premarket trade MarketWatch
Aug-13-19 04:28PM  Adaptive Biotech loss narrower than expected on first post IPO report MarketWatch
04:05PM  Adaptive Biotechnologies Corporation Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-12-19 06:57PM  Ron Baron Comments on Adaptive Biotechnologies Corp
Aug-09-19 04:56PM  New Listings Stink Up Earnings Season After Reports Disappoint Bloomberg
Aug-07-19 05:20PM  Adaptive Biotechnologies signs lease for new Seattle headquarters American City Business Journals +7.17%
08:30AM  Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattles Growing Biotech Hub GlobeNewswire
Aug-01-19 04:15PM  Adaptive Biotechnologies to Report Second Quarter Financial Results on August 13, 2019 GlobeNewswire
Jul-31-19 04:15PM  Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers GlobeNewswire
Jul-24-19 07:10AM  3 Stocks the World's Best Investors Are Buying Right Now Motley Fool
Jul-12-19 03:55PM  Sound Pharmaceuticals targets IPO in 2020 American City Business Journals
Jul-01-19 04:32PM  Why Freeport-McMoRan, Coty, and Adaptive Biotechnologies Slumped Today Motley Fool -16.98%
04:05PM  Adaptive Biotechnologies Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire
10:28AM  Adaptive Biotechnologies CEO Chad Robins on that crazy IPO and working with his older brother MarketWatch
Jun-28-19 03:14PM  Recent IPOs show investor appetite is strong for biotechs Yahoo Finance +19.85%
09:25AM  Physicist and His Financier Brother Net $5 Billion Biotech IPO Bloomberg
Jun-27-19 04:32PM  Adaptive Biotechnologies Shares Double After IPO
02:48PM  Change Healthcare & Adaptive Biotechnologies pop on first trading day Yahoo Finance Video
11:40AM  Adaptive Biotechnologies IPO: Five things to know MarketWatch
11:25AM  Adaptive Biotech and BridgeBio shares rocket higher on their first day of trade MarketWatch
11:14AM  Adaptive Biotechnologies starts trading today Yahoo Finance Video
08:31AM  Adaptive Biotechnologies prices IPO at $20 a share, above previous range of $18 to $19 MarketWatch
07:00AM  Adaptive Biotechnologies Corporation (Nasdaq: ADPT) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
02:20AM  Adaptive Biotechnologies takes flight in IPO debut Financial Times
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.